NCT06115005

Treatment of Challenging Macular Holes Using Plasma Rich in Growth Factors

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Minia University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Aim of the Study:To report the structural and visual outcomes of plasma rich in growth factors in closure of challenging macular holes

Detailed description

Challenging full thickness macular holes ( FTMH) include : Recurrent FTMH Persistent (refractory) FTMH Macular holes in eyes with pathological myopia Large macular holes with an inner diameter of more than 650 µm. Plasma rich in growth factors (PRGF) is characterized by a moderate concentration of platelets, in the absence of leukocytes. This absence of leukocytes is based on the fact that they synthesize matrix metalloproteinases, free radicals, and proinflammatory cytokines, which do not contribute and even impair the altered tissue regeneration Aim of the Study:To report the structural and visual outcomes of plasma rich in growth factors in closure of challenging macular holes

Conditions

• Macular Holes

Interventions

Type	Name	Description
BIOLOGICAL	Plasma rich in growth factors ( PRGF )	Plasma rich in growth factors (PRGF) is characterized by a moderate concentration of platelets, in the absence of leukocytes. This absence of leukocytes is based on the fact that they synthesize matrix metalloproteinases, free radicals, and proinflammatory cytokines, which do not contribute and even impair the altered tissue regeneration

Timeline

• Start date: 2022-06-01
• Primary completion: 2023-12-31
• Completion: 2024-08-01
• First posted: 2023-11-02
• Last updated: 2023-11-02

Locations

1 site across 1 country: Egypt